Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
GSK and Save the Children call for developing country innovations to enter $1 million award
GSK and Save the Children today launched their fourth annual $1 million Healthcare Innovation Award.
GSK announces start of phase I oncology study with its ICOS agonist antibody
The start of a phase I clinical trial with GSK3359609, an investigational inducibile T-cell costimulator (ICOS) agonist antibody
FULFIL study shows superiority of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in improving lung function and health-related quality of life in COPD patients
FULFIL - Lung FUnction and quality of LiFe assessment in COPD with closed trIpLe therapy
Executive Director Change
Dr Moncef Slaoui, Chairman, Vaccines, has indicated to the Board his intention to retire from the Company in 2017.
ViiV Healthcare announces FDA approval to lower the weight limit for dolutegravir in children and adolescents living with HIV
The US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for dolutegravir 10mg and 25mg oral tablets.
GSK announces phase III study of sirukumab meets both co-primary endpoints in patients with rheumatoid arthritis
The results from the positive SIRROUND-D study are being presented at the Annual European Congress of Rheumatology (EULAR 2016) in London.
New Phase III data shows greater treatment response with GSK’s Benlysta® (belimumab) vs placebo in patients with highly active SLE
BLISS-SC builds on an extensive clinical trial programme for belimumab, which is the largest clinical programme in SLE to date.
ViiV Healthcare announces public tender agreement with Botswana Ministry of Health for dolutegravir
Agreement supports the first ‘Treat All’ programme for HIV in sub-Saharan Africa, where 70% of people with HIV live
Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD
Acceleration of filing of US New Drug Application now expected by end of 2016
StrimvelisTM receives European marketing authorisation to treat very rare disease, ADA-SCID
GSK, Fondazione Telethon and Ospedale San Raffaele gain approval to provide life-saving gene therapy to patients.
Board and Committee changes
Dr Vivienne Cox, CBE, has been appointed to the Board of the Company as a Non-Executive Director with effect from 1 July 2016.
GSK, Fondazione Telethon and Ospedale San Raffaele announce publication of pivotal safety and efficacy of gene therapy for children with ADA-SCID
GSK today announced the publication in BLOOD of the long-term safety and efficacy data from an analysis of 18 children with ADA-SCID
Salford Lung Study results show COPD patients treated with Relvar® Ellipta® achieve superior reduction in exacerbations compared with ‘usual care’
Pioneering GSK study provides important new data on the effectiveness of Relvar Ellipta (FF/VI) when used in everyday clinical practice.
GSK presents efficacy data for Anoro® Ellipta® in COPD patients who remained symptomatic on tiotropium
GSK and Innoviva, Inc. announce results from data presented at the American Thoracic Society 2016 conference
GSK presents new data from Breo® Ellipta® SUMMIT study in patients with COPD at ATS Conference
GSK presents new data at the American Thoracic Society Conference from two pre-specified analyses from the Study
GSK’s Bexsero®▼achieves primary and secondary endpoints with reduced 3-dose schedule (2+1) in safety and immunogenicity study in infants and children
GSK today presented new data for its meningococcal group B vaccine, Bexsero®,1 [Meningococcal group B Vaccine (rDNA, component, adsorbed)]
European agency endorses antiseptic gel, developed through GSK and Save the Children partnership, for newborn umbilical cord infections in developing countries
Milestone for GSK and Save the Children partnership and its mission to help save the lives of children in the world’s poorest communities
GSK statement on pneumococcal vaccine pricing
For many years we have been working hard, in partnership with others, to develop vaccines against infectious diseases
Results announcement for the first quarter 2016
GSK delivers Q1 performance of £6.2 b (+8% CER), core EPS 19.8p (+8% CER); dividend of 19p 2016 core EPS growth expected to be 10-12% CER
ViiV Healthcare extends Medicines Patent Pool licence agreement for dolutegravir to cover all lower middle-income countries
Follows announcement by majority shareholder GSK to expand graduated approach to patents and intellectual property (IP)